Evidence map›Paper›PMID 34628531›Full record

ReviewCurrent pain and headache reports2021

Medical Cannabis for Headache Pain: a Primer for Clinicians.

Robert A Duarte, Stephen Dahmer, Shayna Y Sanguinetti, Grace Forde, Diana P Duarte, Lawrence F Kobak

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pain and headache reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Natural Products Derived from Cannabis sativa for Pain Management.Handbook of experimental pharmacology · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Robert A DuarteNorthwell Health Physician Partners, Institute for Neurology and Neurosurgery, 611 Northern Blvd, Great Neck, NY, 11021, USA. rduarte@northwell.edu.ORCID http://orcid.org/0000-0001-9933-3785
Stephen DahmerFamily Medicine and Community Health, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Shayna Y SanguinettiDepartment of Neurology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 300 Community Drive, Manhasset, NY, 11030, USA.
Grace FordeNeurological Services, North American Partners in Pain Management, 1991 Marcus Avenue, Lake Success, NY, 11050, USA.
Diana P DuarteThe University at Buffalo, Buffalo, NY, USA.
Lawrence F KobakFrier Levitt Attorneys at Law, Pine Brook, USA.
Donald & Barbara Zucker School of Medicine at Hofstra/Northwell · USNorthwell Health · USQueens University · BDSyosset Hospital · USUniversity at Buffalo, State University of New York · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewPublic acceptance of Cannabis sativa L. (cannabis) as a therapeutic option grows despite lags in both research and clinician familiarity. Cannabis-whether as a medical, recreational, or illicit substance-is and has been commonly used by patients. With ongoing decriminalization efforts, decreased perception of harms, and increased use of cannabis in the treatment of symptoms and disease, it is critical for clinicians to understand the rationale for specific therapies and their medical and practical implications for patients. In view of the opioid crisis, overall patient dissatisfaction, and lack of adherence to current chronic pain and headache therapies, this review provides up-to-date knowledge on cannabis as a potential treatment option for headache pain. RECENT

findingsResearch into the use of cannabinoids for disease treatment have led to FDA-approved drugs for seizures, nausea, and vomiting caused by cancer chemotherapy; and for decreased appetite and weight loss in people with HIV/AIDS. For a wide variety of conditions and symptoms (including chronic pain), cannabis has gained increasing acceptance in society. The effects of cannabidiol (CBD) and tetrahydrocannabinol (THC) in pain pathways have been significantly elucidated. An increasing number of retrospective studies have shown a decrease in pain scores after administration of cannabinoids, as well as long-term benefits such as reduced opiate use. Yet, there is no FDA-approved cannabis product for headache or other chronic pain disorders. More is being done to determine who is likely to benefit from cannabis as well as to understand the long-term effects and limitations of the treatment. Cannabis can refer to a number of products derived from the plant Cannabis sativa L. Relatively well-tolerated, these products come in different configurations, types, and delivery forms. Specific formulations of the plant have been shown to be an effective treatment modality for chronic pain, including headache. It is important for clinicians to know which product is being discussed as well as the harms, benefits, contraindications, interactions, and unknowns in order to provide the best counsel for patients.

Indexed as

CannabisChronic PainMedical MarijuanaHeadacheHumansRetrospective StudiesMedical MarijuanaCannabidiol,Cannabis sativa,CBD,Chronic migraine,Chronic pain,DispensaryEndocannabinoid system,Legislation,Medical marijuana,Migraine treatment,Opioid crisis,Opioids,Tetrahydrocannabinol,THC,

Identifiers

PMID34628531
OpenAlexW3207651526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.